An In Vitro Pre-Clinical MPS Model for Metabolic Associated Steatohepatitis for Drug Efficacy

Explore a 28-minute webinar presented by Christiana Skarlatopoulou, a Scientist at CN Bio, focusing on an in vitro pre-clinical microphysiological system (MPS) model for metabolic associated steatohepatitis (NASH) and drug efficacy testing. Gain insights into the global epidemic of non-alcoholic fatty liver disease (NAFLD) and its progression to NASH, characterized by lipid accumulation, immune cell infiltration, and liver fibrosis. Discover why current preclinical models, primarily animal-based, fail to adequately predict clinical outcomes for NASH treatments. Learn about the urgent need for improved preclinical NASH models and how organ-on-a-chip technology offers a promising alternative method to bridge the gap between preclinical predictions and clinical results. Understand the potential of MPS in revolutionizing drug efficacy testing for NASH and other liver diseases.